Abstract
Background
Beta thalassemia (β-thalassemia) is a hereditary disease caused by defective globin synthesis and can be classified into three categories of minor (β-TMi), intermedia (β-TI), and major (β-TM) thalassemia. The aim of our study is to investigate the effects of β-thalassemia and its treatment methods on different parts of the eye and how early-diagnostic methods of ocular complications in this disorder would prevent further ocular complications in these patients by immediate treatment and diet change.
Methods
We developed a search strategy using a combination of the words Beta thalassemia, Ocular abnormalities, Iron overload, chelation therapy to identify all articles from PubMed, Web of Science, Scopus, and Google Scholar up to December 2018. To find more articles and to ensure that databases were thoroughly searched, the reference lists of selected articles were also reviewed.
Results
Complications such as retinopathy, crystalline lens opacification, color vision deficiency, nyctalopia, depressed visual field, reduced visual acuity, reduced contrast sensitivity, amplitude reduction in a-wave and b-wave in Electroretinography (ERG), and decrease in the Arden ratio in Electrooculography (EOG) have all been reported in β-thalassemia patients undergoing chelation therapy.
Conclusion
Ocular problems due to β-thalassemia may be a result of anemia, iron overload in the body tissue, side effects of iron chelators, and the complications of orbital bone marrow expansion.
Similar content being viewed by others
References
Provan D, Singer CR, Baglin T, Dokal I (2009) Oxford handbook of clinical haematology. Oxford University Press, Oxford
Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61
Olivieri NF, Nathan DG, MacMillan JH et al (1994) Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 331(9):574–578
He X, Hahn P, Iacovelli J et al (2007) Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res 26(6):649–673
Brittenham GM, Griffith PM, Nienhuis AW et al (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331(9):567–573
Bollig C, Schell LK, Rücker G et al (2017) Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev 8:CD007476
Olivieri NF, Brittenham GM, Matsui D et al (1995) Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332(14):918–922
Liaska A, Petrou P, Georgakopoulos CD et al (2016) β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol 16(1):102
Gartaganis S, Ismiridis K, Papageorgiou O, Beratis NG, Papanastasiou D (1989) Ocular abnormalities in patients with β-thalassemia. Am J Ophthalmol 108(6):699–703
Gaba A, D’Souza P, Chandra J, Narayan S, Sen S (1998) Ocular changes in β-thalassemia. Ann Ophthalmol Glaucoma 30(6):357–360
Shahriari H, Ghasemzadeh F, Eshghi P, Masoomian B (2006) Ocular side effects of desferal in patients with β-thalassemia. Bina J Ophthalmol 11:519–523
Taher A, Bashshur Z, Shamseddeen WA et al (2006) Ocular findings among thalassemia patients. Am J Ophthalmol 142(4):704–705
Rahiminejad M, Rahiminejad S, Rahimi M et al (2009) Ocular complication and visual evoked potential in β-thalassemia patients on desferal therapy. Res J Biol Sci 4(8):928–932
Taneja R, Malik P, Sharma M, Agarwal MC (2010) Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol 58(2):125
Dewan P, Gomber S, Chawla H, Rohatgi J (2011) Ocular changes in multi-transfused children with β-thalassaemia receiving desferrioxamine: a case-control study. S Afr J Child Health 5(1):11–14
Nowroozzadeh MH, Kalantari Z, Namvar K, Meshkibaf MH (2011) Ocular refractive and biometric characteristics in patients with thalassaemia major. Clin Exp Optom 94(4):361–366
Jafari R, Heydarian S, Karami H et al (2015) Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian J Ophthalmol 63(9):710
Kumble D, Sekhon PK (2017) Ocular involvement in beta thalassemia major: a prospective study in an Indian cohort. Int J Contemp Pediatr 4(3):780–782
Merchant RH, Punde H, Thacker N, Bhatt D (2017) Ophthalmic evaluation in beta-thalassemia. Indian J Pediatr 84(7):509–514
Barteselli G, Dell’arti L, Finger RP et al (2014) The spectrum of ocular alterations in patients with beta-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum. Ophthalmology 121:709–718
Saif AT, Saif PS, Dabous O (2017) Fundus changes in thalassemia in Egyptian patients. Delta J Ophthalmol 18(1):20
Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127(2):127–139
Jensen C, Tuck S, Agnew J et al (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103(4):911–915
Weatherall DJ, Clegg JB (2008) The thalassaemia syndromes. Wiley, Hoboken
Heydarian S, Jafari R, Karami H (2016) Refractive errors and ocular biometry components in thalassemia major patients. Int Ophthalmol 36(2):267–271
Parentin F, Tonini G, Perissutti P (2004) Refractive evaluation in children with growth defect. Curr Eye Res 28(1):11–15
Parentin F, Perissutti P (2005) Congenital growth hormone deficiency and eye refraction: a longitudinal study. Ophthalmologica 219(4):226–231
Bourla DH, Laron Z, Snir M, Lilos P, Weinberger D, Axer-Siegel R (1197) Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome. Ophthalmology 113(7):e1–e5
Khalaj M, Mahyar A, Jahan Hashemi H, Godsi F (2009) Assessing the refractive errors in beta-thalassemia major patients. J Guilan Univ Med Sci 17(68):42–49
Elkitkat RS, El-Shazly AA, Ebeid WM, Deghedy MR (2018) Relation of anthropometric measurements to ocular biometric changes and refractive error in children with thalassemia. Eur J Ophthalmol 28(2):139–143
Gartaganis S, Georgakopoulos C, Exarchou A et al (2003) Alterations in conjunctival cytology and tear film dysfunction in patients with β-thalassemia. Cornea 22(7):591–597
Arcasoy A, Cavdar AO (1975) Changes of trace minerals (serum iron, zinc, copper and magnesium) in thalassemia. Acta Haematol 53(6):341–346
De Luca C, Filosa A, Grandinetti M, Maggio F, Lamba M, Passi S (1999) Blood antioxidant status and urinary levels of catecholamine metabolites in β-thalassemia. Free Radic Res 30(6):453–462
Borgna-Pignatti C, Cammareri V, De Stefano P, Magrini U (1984) The sicca syndrome in thalassaemia major. Br Med J (Clin Res Ed) 288(6418):668–669
Popescu C, Siganos D, Zanakis E, Padakis A (1998) The mechanism of cataract formation in persons with beta-thalassemia. Oftalmologia (Bucharest, Romania: 1990) 45(4):10–13
Athanasiadis I, Konstantinidis A, Kyprianou I, Robinson R, Moschou V, Kouzi-Koliakos K (2007) Rapidly progressing bilateral cataracts in a patient with beta thalassemia and pellagra. J Cataract Refract Surg 33(9):1659–1661
Dhawan V, KhR K, Marwaha R, Ganguly NK (2005) Antioxidant status in children with homozygous thalassemia. Indian Pediatr 42(11):1141–1145
Marsili S, Salganik RI, Albright CD et al (2004) Cataract formation in a strain of rats selected for high oxidative stress. Exp Eye Res 79(5):595–612
Mehdizadeh M, Nowroozzadeh MH (2009) Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption. Clin Exp Optom 92(4):392–394
Aksoy A, Aslan L, Aslankurt M et al (2014) Retinal fiber layer thickness in children with thalassemia major and iron deficiency anemia. Semin ophthalmol 29(1):22–26
Bhoiwala DL, Dunaief JL (2016) Retinal abnormalities in β-thalassemia major. Surv Ophthalmol 61(1):33–50
Genead MA, Fishman GA, Anastasakis A, Lindeman M (2010) Macular vitelliform lesion in desferrioxamine-related retinopathy. Doc Ophthalmol 121:161–166
Georgakopoulos CD, Tsapardoni F, Kostopoulou EV, Makri OE (2018) Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature. BMC Ophthalmol 18(1):246
Gonzales CR, Lin AP, Engstrom RE, Kreiger AE (2004) Bilateral vitelliform maculopathy and deferoxamine toxicity. Retina (Philadelphia, Pa) 24(3):464–467
Viola F, Barteselli G, Dell’Arti L et al (2014) Multimodal imaging in deferoxamine retinopathy. Retina (Philadelphia, Pa) 34(7):1428–1438
Finger RP, Issa PC, Ladewig MS et al (2009) Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol 54(2):272–285
Goodman G, von Sallmann L, Holland MG (1957) Ocular manifestations of sickle-cell disease. AMA Arch Ophthalmol 58(5):655–682
Aessopos A, Farmakis D, Loukopoulos D (2002) Elastic tissue abnormalities resembling pseudoxanthoma elasticum in β-thalassemia and the sickling syndromes. Blood 99(1):30–35
Hamlin N, Beck K, Bacchelli B, Cianciulli P, Pasquali-Ronchetti I, Le Saux O (2003) Acquired Pseudoxanthoma elasticum-like syndrome in β-thalassaemia patients. Br J Haematol 122(5):852–854
Bunda S, Kaviani N, Hinek A (2005) Fluctuations of intracellular iron modulate elastin production. J Biol Chem 280(3):2341–2351
Martin L, Douet V, VanWart CM, Heller MB, Le Saux O (2011) A mouse model of β-thalassemia shows a liver-specific down-regulation of ABCC6 expression. Am J Pathol 178(2):774–783
Jiang Q, Matsuzaki Y, Li K, Uitto J (2006) Transcriptional regulation and characterization of the promoter region of the human ABCC6 gene. J Investig Dermatol 126(2):325–335
Georgalas I, Papaconstantinou D, Koutsandrea C et al (2009) Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag 5:81
Aessopos A, Stamatelos G, Savvides P et al (1989) Angioid streaks in homozygous β-thalassemia. Am J Ophthalmol 108(4):356–359
Gibson J, Chaudhuri P, Rosenthal A (1983) Angioid streaks in a case of beta thalassaemia major. Br J Ophthalmol 67(1):29
Kinsella FP, Mooney DJ (1988) Angioid streaks in beta thalassaemia minor. Br J Ophthalmol 72(4):303–304
Aessopos A, Floudas CS, Kati M et al (2008) Loss of vision associated with angioid streaks in β-thalassemia intermedia. Int J Hematol 87(1):35–38
Issa PC, Finger RP, Götting C, Hendig D, Holz FG, Scholl HP (2010) Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology 117(7):1406–1414
Incorvaia C, Parmeggiani F, Costagliola C, Perri P, D’Angelo S, Sebastiani A (2003) Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by β-thalassaemia major. Eye 17(3):324
Sorcinelli R, Sitzia A, Figus A, Lai M (1990) Ocular findings in beta-thalassemia. Metab Pediatr Syst Ophthalmol (New York, NY: 1985) 13(1):23–25
Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma J-X (2005) RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci 102(35):12413–12418
Błasiak J, Skłodowska A, Ulińska M, Szaflik J (2009) Iron and age-related macular degeneration. Klin Oczna 111(4–6):174–177
Mehta S, Dunaief JL (2012) The role of iron in retinal diseases. In: Studies on retinal and choroidal disorders. Humana Press, pp 259–275
Davies S, Hungerford J, Arden G, Marcus R, Miller M, Huehns E (1983) Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 322(8343):181–184
Olivieri NF, Buncic JR, Chew E et al (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314(14):869–873
Baath JS, Lam WC, Kirby M, Chun A (2008) Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina (Philadelphia, Pa) 28:894–899
Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S (2002) The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109:164–171
Wu C-H, Yang C-P, Lai C-C, Wu W-C, Chen Y-H (2014) Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. BMC Ophthalmol 14(1):88
Gelman R, Kiss S, Tsang SH (2014) Multimodal imaging in a case of deferoxamine induced maculopathy. Retin Cases Brief Rep 8(4):306
Van Bol L, Alami A, Benghiat FS, Rasquin F (2014) Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases. Retin Cases Brief Rep 8(2):97–102
Eleftheriadou M, Theodossiadis P, Rouvas A, Alonistiotis D, Theodossiadis G (2012) New optical coherence tomography fundus findings in a case of beta-thalassemia. Clin Ophthalmol (Auckland, NZ) 6:2119
Simon S, Athanasiov PA, Jain R, Raymond G, Gilhotra JS (2012) Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol 60(4):315
Viola F, Barteselli G, Dell’Arti L et al (2012) Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology 119(8):1693–1700
Arora A, Wren S, Gregory Evans K (2004) Desferrioxamine related maculopathy: a case report. Am J Hematol 76(4):386–388
Meerpohl JJ, Antes G, Rücker G et al (2012) Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev (2)
Galanello R (2007) Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag 3(5):795
Song D, Zhao L, Li Y et al (2014) The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci 55:4525–4532
Gartaganis SP, Zoumbos N, Koliopoulos JX, Mela EK (2000) Contrast sensitivity function in patients with beta-thalassemia major. Acta Ophthalmol Scand 78(5):512–515
Ghazanfari A, Jafarzadehpour E, Heydarian S, Dailami KN, Karami H (2018) Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox. J Optom 12:168–173
Spyridon G, Ioannis A, Nikolaos C et al (2010) Contrast sensitivity in patients with beta-thalassemia major and sickle cell disease under regular transfusions and treatment with desferrioxamine. Open Ophthalmol J 4:39
Regan D, Neima D (1983) Low-contrast letter charts as a test of visual function. Ophthalmology 90(10):1192–1200
Woods RL, Tregear SJ, Mitchell RA (1998) Screening for ophthalmic disease in older subjects using visual acuity and contrast sensitivity1. Ophthalmology 105(12):2318–2326
Aminoff MJ (2012) Electrodiagnosis in clinical neurology. Elsevier, Amsterdam
Arden G, Fojas M (1962) Electrophysiological abnormalities in pigmentary degenerations of the retina: assessment of value and basis. Arch Ophthalmol 68(3):369–389
Scholl HP, Zrenner E (2000) Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 45(1):29–47
Dettoraki M, Kattamis A, Ladas I et al (2017) Electrophysiological assessment for early detection of retinal dysfunction in beta-thalassemia major patients. Graefe’s Arch Clin Exp Ophthalmol 255(7):1349–1358
Economou M, Zafeiriou DI, Kontopoulos E et al (2006) Neurophysiologic and intellectual evaluation of beta-thalassemia patients. Brain Dev 28(1):14–18
El-Shazly AA, Ebeid WM, Elkitkat RS, Deghedy MR (2017) Electroretinographic and visual-evoked potential changes in relation to chelation modality in children with thalassemia. Retina (Philadelphia, Pa) 37(6):1168–1175
Gelmi C, Borgna-Pignatti C, Franchin S, Tacchini M, Trimarchi F (1988) Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major. Ophthalmologica 196(1):29–34
Wong V, Li A, Lee A (1993) Neurophysiologic study of β-thalassemia patients. J Child Neurol 8(4):330–335
Zafeiriou DI, Kousi AA, Tsantali CT et al (1998) Neurophysiologic evaluation of long-term desferrioxamine therapy in beta-thalassemia patients. Pediatr Neurol 18(5):420–424
De Virgiliis S, Congia M, Turco M et al (1988) Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 63(3):250–255
Marciani M, Cianciulli P, Stefani N et al (1991) Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. Haematologica 76(2):131–134
Aarabi B, Haghshenas M, Rakeii V (1998) Visual failure caused by suprasellar extramedullary hematopoiesis in beta thalassemia: case report. Neurosurgery 42(4):922–925
Stamboulis E, Vlachou N, Drossou-Servou M et al (2004) Axonal sensorimotor neuropathy in patients with β-thalassaemia. J Neurol Neurosurg Psychiatry 75(10):1483–1486
Arden G, Wonke B, Kennedy C, Huehns E (1984) Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 68(12):873–877
Jiang C, Hansen RM, Gee BE, Kurth SS, Fulton AB (1998) Rod and rod mediated function in patients with β-thalassemia major. Doc Ophthalmol 96(4):333–346
Orton R, Sulh H (1985) Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 20(4):153–156
Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S, Group DRS (2002) The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109(1):164–171
Ravelli M, Scaroni P, Mombelloni S et al (1990) Acute visual disorders in patients on regular dialysis given desferrioxamine as a test. Nephrol Dial Transpl 5(11):945–949
Kertes PJ, Lee TK, Coupland SG (2004) The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. Can J Ophthalmol 39(6):656–661
Rudd C, Evans PJ, Peeney A (1953) Ocular complications in thalassaemia minor. Br J Ophthalmol 37(6):353
Angelucci E, Brittenham GM, Mclaren CE et al (2000) Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343(5):327–331
Musallam KM, Cappellini MD, Taher AT (2013) Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol 20(3):187–192
Musallam KM, Cappellini MD, Wood JC, Taher AT (2012) Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 26:S16–S19
Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD (2001) Membrane-bound iron contributes to oxidative damage of β-thalassaemia intermedia erythrocytes. Br J Haematol 112(1):48–50
Varano M, Scassa C (1998) Scanning laser ophthalmoscope microperimetry. Semin ophthalmol 13(4):203–209
Issa PC, Finger RP, Holz FG, Scholl HP (2009) Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci 50(12):5913–5918
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Human and animal rights
Not applicable.
Informed consent
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Heydarian, S., Jafari, R., Dailami, K.N. et al. Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies. Int Ophthalmol 40, 511–527 (2020). https://doi.org/10.1007/s10792-019-01189-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-019-01189-3